Center for Cell Engineering: Center for Cell Engineering Holds First Annual Retreat

We are living in very exciting times for cell engineering and cell therapies,” Sloan Kettering Institute investigator Michel Sadelain told a standing-room-only audience in Memorial Hospital’s Hoffmann Auditorium as he opened the first annual retreat of Memorial Sloan Kettering Cancer Center’s newly established Center for Cell Engineering (CCE). The afternoon-long January 10 event featured presentations by four Memorial Sloan Kettering scientists and two researchers from other institutions that focused on strategies for using the body’s own cells to treat disease.

A number of human cell types are currently under investigation in laboratories for the treatment of cancer as well as genetic disorders, infectious diseases, and degenerative disorders. The CCE was established in 2007 to take advantage of recent advances in human cell engineering and to bring together researchers investigating immune engineering and stem cell biology. Dr. Sadelain, a Member in Sloan Kettering Institute’s Molecular Pharmacology and Chemistry Program, heads the CCE and acted as moderator, along with Memorial Sloan Kettering’s Department of Pediatrics Chair Richard J. O’Reilly, who also heads the Pediatric Bone Marrow Transplant Service.

The inaugural retreat concentrated on immune engineering, which involves manipulating immune cells in the laboratory to enhance their therapeutic effect after they are infused into a patient. The speakers addressed the use of T cells — a type of immune cell — to stimulate the body’s immune response to cancer while reducing the risk that the immune cells attack normal tissues.

Several presenters described techniques for isolating and expanding specific T cell subsets from a donor before infusing them into a patient who has received a stem cell transplant. These approaches aim to prevent graft-versus-host disease, a potentially life-threatening condition in which transplanted immune cells attack a recipient’s tissues.

Other speakers addressed novel strategies to generate active antitumor T cells derived from the patient (thus avoiding the risk of graft-versus-host disease) by stimulating them with engineered cells or targeting them through genetic engineering. Memorial Sloan Kettering investigators recently initiated a clinical study using genetically engineered patient T cells to target leukemia.

Dr. O’Reilly noted that the recent advances add to a “burgeoning development of new approaches designed to enhance the ability of patients’ own immune systems to resist disease.

Keynote presentations were made by Bruce R. Blazar, professor of pediatrics at the University of Minnesota, and Carl H. June, professor of pathology and laboratory medicine at the University of Pennsylvania. Memorial Sloan Kettering scientists and physicians who presented were Marcel R. van den Brink, Chief of the Adult Bone Marrow Transplant Service; Isabelle Riviére, Director of the Gene Transfer and Somatic Cell Engineering Facility; medical oncologist Guenther Koehne; and medical oncologist Renier J. Brentjens.